How do you approach patients with low ER positive (1 - 9%) breast cancer?

How do you counsel them on risk in the curative setting? Do you approach treatment in the metastatic setting any different than patients with >/= 10% ER positivity?

Answer from: Medical Oncologist at Community Practice

The EBCTCG meta-analysis on adjuvant tamoxifen found benefit with tamoxifen use across all subgroups of ER expression, including the low expressors (1-9%). The absolute benefit of tamoxifen may not be significantly high. In my practice, I do offer anti-estrogen therapy in such a setting, but have a ...

Comments

Medical Oncologist at Indiana Univ Simon Cancer Center
I typically have not sent Oncotype testing on thes...

Please select the option that best describes you:

How do you approach patients with low ER positive (1 - 9%) breast cancer?

Related Questions